Company intelligence / Profile preview
Vasogen
Mississauga, Canada
- Ownership
- Private
- Employees
- ~250
- Development stage
- Other
01
Overview
Vasogen developed immune modulation therapies targeting chronic inflammation in cardiovascular and neurological conditions. Its lead product, Celacade, completed a large Phase III trial in chronic heart failure but failed to meet the primary endpoint overall; however, a major sub-group did show benefit. Celacade received CE Mark approval in the EU and was partnered with Grupo Ferrer Internacional for commercialization in Europe and parts of Latin America. The company also had an early-stage neurodegenerative disease candidate, VP025. In 2009, Vasogen merged with IntelliPharmaCeutics to form IntelliPharmaCeutics International Ltd., effectively ending its independent operations.
- Therapeutic areas
- NeurologyCardiovascular
- Modalities
- DeviceSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Grupo Ferrer Internacional
Beyond the preview
Go deeper on Vasogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasogen.